<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>OBJECTIVE: To report a case of <z:hpo ids='HP_0001915'>aplastic anemia</z:hpo> that developed during <z:chebi fb="0" ids="9588">ticlopidine</z:chebi> treatment </plain></SENT>
<SENT sid="1" pm="."><plain>CASE SUMMARY: An 84-year-old woman was started on <z:chebi fb="0" ids="9588">ticlopidine</z:chebi> for secondary <z:hpo ids='HP_0001297'>stroke</z:hpo> prevention </plain></SENT>
<SENT sid="2" pm="."><plain>Within six weeks of initiating <z:chebi fb="0" ids="9588">ticlopidine</z:chebi> therapy she developed <z:hpo ids='HP_0001915'>aplastic anemia</z:hpo> </plain></SENT>
<SENT sid="3" pm="."><plain>She was hospitalized and received empiric antibiotics, antifungal agents, blood transfusions, platelets, and granulocyte colony-stimulating factor </plain></SENT>
<SENT sid="4" pm="."><plain>The patient died on day 76 after beginning <z:chebi fb="0" ids="9588">ticlopidine</z:chebi> </plain></SENT>
<SENT sid="5" pm="."><plain>DISCUSSION: Hematologic effects such as <z:hpo ids='HP_0001875'>neutropenia</z:hpo>, <z:hpo ids='HP_0001873'>thrombocytopenia</z:hpo>, <z:mp ids='MP_0000334'>agranulocytosis</z:mp>, thrombotic thrombocytopenic <z:hpo ids='HP_0000979'>purpura</z:hpo>, and <z:hpo ids='HP_0001876'>pancytopenia</z:hpo> have been described with the use of <z:chebi fb="0" ids="9588">ticlopidine</z:chebi> </plain></SENT>
<SENT sid="6" pm="."><plain>Previous case reports have associated <z:chebi fb="0" ids="9588">ticlopidine</z:chebi> with the development of <z:hpo ids='HP_0001915'>aplastic anemia</z:hpo> </plain></SENT>
<SENT sid="7" pm="."><plain>CONCLUSIONS: <z:chebi fb="0" ids="9588">Ticlopidine</z:chebi> can produce fatal hematologic adverse effects, and its use should be reserved as second-line therapy </plain></SENT>
</text></document>